tradingkey.logo
tradingkey.logo
Search

Sironax Grants Novartis Exclusive Option To Acquire Its Brain Delivery Platform While Retaining Rights To Advance Selected Therapeutic Assets

ReutersJul 9, 2025 12:04 PM
facebooktwitterlinkedin
View all comments0

- Novartis AG NOVN.S:

  • SIRONAX GRANTS NOVARTIS EXCLUSIVE OPTION TO ACQUIRE ITS BRAIN DELIVERY PLATFORM WHILE RETAINING RIGHTS TO ADVANCE SELECTED THERAPEUTIC ASSETS

  • NOVARTIS AG - NOVARTIS WILL EVALUATE BDM PLATFORM WITHIN AN OPTION PERIOD

  • NOVARTIS AG - SIRONAX IS ELIGIBLE TO RECEIVE UP TO $175 MILLION IN UPFRONT AND NEAR-TERM PAYMENTS

  • NOVARTIS AG - SIRONAX RETAINS RIGHT TO CONTINUE DEVELOPING SELECTED THERAPEUTIC ASSETS USING PLATFORM

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Comments (0)

Click the $ button, enter the symbol, and select to link a stock, ETF, or other ticker.

0/500
Commenting Guidelines
Loading...

Recommended Articles

Tradingkey
KeyAI